

**Department of Health and Human Services
National Institutes of Health
National Cancer Institute
Division of Cancer Treatment and Diagnosis**

The National Cancer Institute (NCI) is seeking expressions of interest from highly qualified physicians and physician-scientists for potential opportunities within the Cancer Therapy Evaluation Program (CTEP). The CTEP is part of the Division of Cancer Treatment and Diagnosis (DCTD) <https://dctd.cancer.gov>. Potential positions may be available within CTEP's Clinical Investigations Branch (CIB) and Investigational Drug Branch (IDB).

CTEP's mission is to improve the lives of people with cancer by identifying better ways to treat, control, and cure cancer. CTEP supports an extensive national cancer research program and sponsors clinical trials evaluating novel anticancer agents, with an emphasis on translating scientific discoveries into effective cancer therapies. This work includes the development and oversight of clinical trials, evaluation of investigational agents, and collaboration with investigators and research partners across the national oncology community.

CTEP is particularly interested in physicians and physician-scientists with clinical and research expertise in areas that may include:

- Medical oncology and/or hematologic malignancies
- Pediatric oncology
- Early drug development and experimental therapeutics, including small-molecule agents
- Breast cancer
- Melanoma
- Clinical trial design, development, and scientific oversight
- Translational and precision oncology

Physicians within CTEP have opportunities to provide scientific, clinical, and programmatic leadership for NCI-supported cancer clinical research. Responsibilities may include developing and overseeing portfolios of clinical trials and investigational agents; evaluating scientific concepts and clinical trial proposals; providing clinical and scientific expertise in assigned disease or therapeutic areas; and collaborating with investigators, academic institutions, industry, federal partners, and NCI-supported clinical trial networks.

The Clinical Investigations Branch (CIB) develops and oversees clinical trial portfolios and supports the evaluation of novel therapeutic strategies across NCI-sponsored clinical research. CIB also provides oversight of pediatric cancer clinical trial portfolios, including the incorporation of molecular characterization and novel therapeutic approaches into trials for children with cancer.

The Investigational Drug Branch (IDB) develops and oversees portfolios of novel anticancer agents and provides scientific and clinical leadership for their evaluation through NCI's experimental therapeutics and clinical trials programs.

Through these roles, physicians have the opportunity to contribute to the development of innovative cancer therapies and help shape national clinical research strategies designed to improve outcomes for people with cancer.

Candidates should possess an M.D. or equivalent medical degree with an active U.S. medical license and demonstrate expertise in oncology, clinical research, experimental therapeutics, or a related area. Candidates with experience in clinical trial development and oversight, multidisciplinary or translational research, drug development, and/or leadership of collaborative oncology research programs are encouraged to express interest.

This is an exploratory advertisement to gauge interest and develop a potential candidate pool. A vacancy announcement (VA) to fill these positions will be posted on USAJOBS.gov at a later date.

This is a full-time government position in Rockville, Maryland. Candidates must be U.S. citizens. Compensation for this position is commensurate with the individual's qualifications as permitted within Federal Government appointments.

Interested candidates are encouraged to submit a curriculum vitae or résumé and a brief statement describing their clinical/research expertise and area(s) of interest to NCIDCTDvacancyinquiry@mail.nih.gov.

DHHS, NIH, and NCI are Equal Opportunity Employers



**NATIONAL
CANCER
INSTITUTE**